News

Lexington Biosciences Converts Amounts Owed to Unsecured Demand Loans

VANCOUVER, BRITISH COLUMBIA – October 4, 2019 – Lexington Biosciences, Inc. (CSE: LNB) (the “Company” or “Lexington”) announces that it has reached agreement with third parties as well as certain directors and officers (collectively the “lenders”) of the Company to convert previous advances and unpaid amounts for services received of $654,186, in aggregate, into unsecured

Read More

Lexington Biosciences to Consolidate its Common Shares

VANCOUVER, BRITISH COLUMBIA – April 25, 2018 – Lexington Biosciences, Inc. (CSE: LNB) (OTCQB: LXGTF) (the “Company” or “Lexington”) announces that effective at the opening of markets on April 26, 2019, the Company has consolidated its outstanding common shares (the “Shares”) on the basis of one (1) post‐consolidated Share for every ten (10) pre‐consolidated Shares

Read More

Lexington Biosciences Provides Update on Financial Situation

VANCOUVER, BRITISH COLUMBIA – April 2, 2018 – Lexington Biosciences, Inc. (CSE: LNB) (OTCQB: LXGTF) (the “Company” or “Lexington”) announced on February 14, 2019 that it had been unable to secure the necessary financing to advance the development of its HeartSentry technology.  The Company is currently considering its options, which may include selling the HeartSentry

Read More

Lexington Biosciences Announces Termination of Private Placement

VANCOUVER, British Columbia, Feb. 14, 2019 — Lexington Biosciences, Inc. (CSE: LNB) (OTCQB: LXGTF) (the “Company” or “Lexington”) announces that, despite numerous attempts over the past 9 months, it has been unable to secure the necessary funding to advance the development of its HeartSentry technology. As a result, the Company is terminating its previously announced private placement

Read More

Lexington Provides Q3 Corporate Review

VANCOUVER, British Columbia, Oct. 23, 2018 — Lexington Biosciences, Inc. (CSE: LNB) (OTCQB: LXGTF) (the “Company” or “Lexington”), a development-stage medical device company, is pleased to review activities undertaken during Q3 of 2018. Over the summer, the Company completed its first phase of clinical testing at Diablo Clinical Research. The results of the study validated

Read More

Lexington Announces Non-Brokered Private Placement

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN VANCOUVER, British Columbia, Aug. 27, 2018 — Lexington Biosciences, Inc. (CSE: LNB) (OTCQB: LXGTF) (the “Company” or “Lexington”) announces that it has terminated its agreement with Gravitas Securities Inc. and Canaccord Genuity Corp. in connection with its previously announced brokered private placement (see news releases

Read More

Lexington Announces First Multicenter Clinical Study Site

Company embarks on pivotal clinical study VANCOUVER, British Columbia, Aug. 21, 2018 — Lexington Biosciences, Inc. (CSE: LNB) (OTCQB: LXGTF) (the “Company” or “Lexington”), a development-stage medical device company, is pleased to announce the Medical College of Wisconsin as the first site in its multicenter clinical study for the HeartSentry portable cardiovascular health monitor. “Our

Read More

BLOG: The Endothelium: Getting to the “Heart” of Cardiovascular Disease

Despite positive developments in medication and lifestyle changes to reduce risk factors associated with cardiovascular disease (CVD) and atherosclerosis (plaque build-up in arteries), stroke and heart attack remain the leading cause of death worldwide. Innovation in medical care and medical devices will likely play a central role in improving long term cardiovascular health outcomes. Over

Read More

Lexington Biosciences Receives HeartSentry USPTO Patent Approval

Patent encompasses functional claims, underlying science and methods   VANCOUVER, British Columbia, July 25, 2018 — Lexington Biosciences, Inc. (CSE:LNB) (OTCQB:LXGTF) (the “Company” or “Lexington”), a development-stage medical device company, is pleased to announce the issuance of U.S. Patent No. 10,028,664, which covers aspects of its HeartSentry device. “Today’s news is a big deal for

Read More

1 2 3 5

Archives

Categories

Newsletter Updates

If you haven’t already done so, signup here to receive future editions and the latest company news direct to your inbox.

Latest News